ZA876819B - Neuroleptic acetic acid ester - Google Patents

Neuroleptic acetic acid ester

Info

Publication number
ZA876819B
ZA876819B ZA876819A ZA876819A ZA876819B ZA 876819 B ZA876819 B ZA 876819B ZA 876819 A ZA876819 A ZA 876819A ZA 876819 A ZA876819 A ZA 876819A ZA 876819 B ZA876819 B ZA 876819B
Authority
ZA
South Africa
Prior art keywords
acetic acid
acid ester
neuroleptic
haloperidol
compounds
Prior art date
Application number
ZA876819A
Other languages
English (en)
Inventor
Jens Kristian Perregaard
Kristian Perregaard Jens
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA876819B publication Critical patent/ZA876819B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA876819A 1986-09-11 1987-09-11 Neuroleptic acetic acid ester ZA876819B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868621892A GB8621892D0 (en) 1986-09-11 1986-09-11 Organic compound

Publications (1)

Publication Number Publication Date
ZA876819B true ZA876819B (en) 1988-06-29

Family

ID=10604021

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA876819A ZA876819B (en) 1986-09-11 1987-09-11 Neuroleptic acetic acid ester

Country Status (16)

Country Link
US (1) US4855307A (da)
EP (1) EP0260070B1 (da)
JP (1) JPS6377857A (da)
AT (1) ATE92917T1 (da)
AU (1) AU591334B2 (da)
DE (1) DE3786966T2 (da)
DK (1) DK166320C (da)
ES (1) ES2058120T3 (da)
FI (1) FI88155C (da)
GB (1) GB8621892D0 (da)
IE (1) IE60902B1 (da)
IL (1) IL83819A (da)
NO (1) NO169893C (da)
NZ (1) NZ221711A (da)
PT (1) PT85678B (da)
ZA (1) ZA876819B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742580C1 (de) * 1987-12-16 1989-05-11 Schaper & Bruemmer Gmbh Verwendung des alpha,alpha-Diphenyl-alpha-(3-carboxy-propionyloxy)-essigsaeure-4-(N-methylpiperidyl)-esters zur Behandlung hypertoner Funktionszustaende im Bereich der Harnblase
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
EP1263729B1 (en) 2000-03-06 2006-12-20 Acadia Pharmaceuticals Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
EP1787984B1 (en) * 2000-03-06 2016-10-19 Acadia Pharmaceuticals Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
KR20050008846A (ko) 2002-06-24 2005-01-21 아카디아 파마슈티칼스 인코포레이티드 세로토닌 수용체 제제로서의 n-치환된 피페리딘 유도체
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
CA2512639C (en) 2003-01-16 2012-10-30 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
KR101260036B1 (ko) 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 N-(4-플루오로벤질)-n-(1-메틸피페리딘-4-일)-n'-(4-(2-메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
EP3325444B1 (en) 2015-07-20 2021-07-07 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB895309A (en) * 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3408356A (en) * 1965-08-31 1968-10-29 Squibb & Sons Inc Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like
DE1695194A1 (de) * 1966-07-11 1971-03-18 Hoffmann La Roche Verfahren zur Herstellung von Piperidinderivaten
US4070473A (en) * 1973-01-26 1978-01-24 Ab Ferrosan Piperidino-butyrophenones
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative

Also Published As

Publication number Publication date
IE60902B1 (en) 1994-08-24
AU7823287A (en) 1988-03-17
NO169893B (no) 1992-05-11
EP0260070B1 (en) 1993-08-11
NO873785D0 (no) 1987-09-10
NO169893C (no) 1992-08-19
PT85678B (pt) 1990-05-31
EP0260070A1 (en) 1988-03-16
DK166320B (da) 1993-04-05
GB8621892D0 (en) 1986-10-15
PT85678A (en) 1987-10-01
IL83819A (en) 1992-02-16
ATE92917T1 (de) 1993-08-15
AU591334B2 (en) 1989-11-30
ES2058120T3 (es) 1994-11-01
US4855307A (en) 1989-08-08
FI88155C (fi) 1993-04-13
DE3786966T2 (de) 1994-03-17
DK166320C (da) 1993-08-23
DK479587A (da) 1988-03-12
NO873785L (no) 1988-03-14
DE3786966D1 (de) 1993-09-16
FI873924A0 (fi) 1987-09-10
IE872366L (en) 1988-03-11
DK479587D0 (da) 1987-09-11
NZ221711A (en) 1989-11-28
FI88155B (fi) 1992-12-31
IL83819A0 (en) 1988-02-29
JPS6377857A (ja) 1988-04-08
FI873924L (fi) 1988-03-12

Similar Documents

Publication Publication Date Title
AU591334B2 (en) Neuroleptic acetic acid ester
DE2963183D1 (en) 1,4-dihydropyridine compounds, their preparation, pharmaceutical compositions containing said compounds and preparation of these compositions
ES2074846T3 (es) Nuevas naftil-etil-ureas y naftil-etil-tioureas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
DK34289A (da) Madlavnings/salatolie
DE3572807D1 (en) A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use
DK0614362T5 (da) Farmaceutiske præparater på basis af ebastin eller dermed analoge forbindelser
ATE22804T1 (de) Pharmazeutische zusammensetzung.
ES2062376T3 (es) Formulaciones de comprimidos que contienen fosinopril.
NZ240271A (en) Hexahydro-(4-(4-(2-methoxyphenyl)-piperazine-1-yl)-2-phenylbutyryl)azepine; pharmaceutical compositions and preparatory processes
FI881609A0 (fi) Dihydropyridinamider, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
ATE78693T1 (de) Ein dideoxynukleosid enthaltendes arzneimittel.
NO891260L (no) Fremgangsmaate for fremstilling av 4-aryl-4-piperidin (eller pyrrolidin eller hexahydroazepin) carbinoler.
EP0191724A3 (de) 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DK149888C (da) Analogifremgangsmaade til fremstilling af 1-(1,3,4-oxadiazolyl-2-phenoxy)-3-(4-phenylpiperazinyl)-propan-2-oler eller fysiologisk acceptable syreadditionssalte heraf
EP0424158A3 (en) Hair treatment composition
DE69715733D1 (de) Verfahren zur Herstellung von 5-Brom-2-Fluorbenzolboronsäure
DE3762854D1 (de) Pharmazeutische zusammensetzungen mit inhalt von 5-phenyl-1,3-dioxoalkenylverbindungen.
NO922795L (no) Anvendelse av 1,4-dihydropyridiner ved diabetes